Evidence map›Paper›PMID 29367259›Full record

ArticleMolecular pharmacology2018

Pharmacogenomics of Chemically Distinct Classes of Keap1-Nrf2 Activators Identify Common and Unique Gene, Protein, and Pathway Responses In Vivo.

Ryan S Wible, Quynh T Tran, Samreen Fathima, Carrie H Sutter, Thomas W Kensler, Thomas R Sutter

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Dual Deletion ofInternational journal of molecular sciences · 2024
    Article
  3. Article
  4. A Point Mutation at C151 ofMolecular pharmacology · 2023
    Article
  5. Article
  6. Review
  7. Nrf2 as a potential target for Parkinson's disease therapy.Journal of molecular medicine (Berlin, Germany) · 2021
    Review
  8. Nrf2 in liver toxicology.Archives of pharmacal research · 2020
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ryan S WibleDepartments of Chemistry (R.S.W., T.R.S.) and Biological Sciences (C.H.S., T.R.S.,) and the W. Harry Feinstone Center for Genomic Research (R.S.W., S.F., T.R.S.), University of Memphis, Memphis, Tennessee; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee (Q.T.T.); Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (T.W.K.); and Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (T.W.K.).
Quynh T TranDepartments of Chemistry (R.S.W., T.R.S.) and Biological Sciences (C.H.S., T.R.S.,) and the W. Harry Feinstone Center for Genomic Research (R.S.W., S.F., T.R.S.), University of Memphis, Memphis, Tennessee; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee (Q.T.T.); Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (T.W.K.); and Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (T.W.K.).
Samreen FathimaDepartments of Chemistry (R.S.W., T.R.S.) and Biological Sciences (C.H.S., T.R.S.,) and the W. Harry Feinstone Center for Genomic Research (R.S.W., S.F., T.R.S.), University of Memphis, Memphis, Tennessee; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee (Q.T.T.); Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (T.W.K.); and Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (T.W.K.).
Carrie H SutterDepartments of Chemistry (R.S.W., T.R.S.) and Biological Sciences (C.H.S., T.R.S.,) and the W. Harry Feinstone Center for Genomic Research (R.S.W., S.F., T.R.S.), University of Memphis, Memphis, Tennessee; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee (Q.T.T.); Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (T.W.K.); and Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (T.W.K.).
Thomas W KenslerDepartments of Chemistry (R.S.W., T.R.S.) and Biological Sciences (C.H.S., T.R.S.,) and the W. Harry Feinstone Center for Genomic Research (R.S.W., S.F., T.R.S.), University of Memphis, Memphis, Tennessee; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee (Q.T.T.); Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (T.W.K.); and Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (T.W.K.).
Thomas R SutterDepartments of Chemistry (R.S.W., T.R.S.) and Biological Sciences (C.H.S., T.R.S.,) and the W. Harry Feinstone Center for Genomic Research (R.S.W., S.F., T.R.S.), University of Memphis, Memphis, Tennessee; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee (Q.T.T.); Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (T.W.K.); and Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (T.W.K.) tsutter@memphis.edu.
University of Tennessee Health Science Center · USUniversity of Memphis · USJohns Hopkins University · US

Funding

Molecular Mechanisms of Chemoprevention: NRF2 SignalingR01CA039416 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KENSLER, THOMAS W · 1985 to 2013
$7.0M
Targeting Nrf2 for Cancer ChemopreventionR35CA197222 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KENSLER, THOMAS W · 2015 to 2021
$6.7M
NCI NIH HHS R01 CA039416NCI NIH HHS R35 CA197222
6 · The paper itself

Abstract

The Kelch-like erythroid-associated protein 1 (Keap1)-NF-E2-related factor 2 (Nrf2) signaling pathway is the subject of several clinical trials evaluating the effects of Nrf2 activation on the prevention of cancer and diabetes and the treatment of chronic kidney disease and multiple sclerosis. 3

Indexed as

AnimalsGene Regulatory NetworksImidazolesKelch-Like ECH-Associated Protein 1MaleMiceMice, Inbred C57BLMice, KnockoutNF-E2-Related Factor 2Oleanolic AcidPharmacogeneticsSignal Transduction1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazoleImidazolesKeap1 protein, mouseKelch-Like ECH-Associated Protein 1Nfe2l2 protein, mouseNF-E2-Related Factor 2Oleanolic Acid

Identifiers

PMID29367259
PMCPMC5832324
OpenAlexW2784795957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.